Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $6.38, for a total value of $10,814.10. Following the completion of the sale, the chief financial officer now owns 339,803 shares of the company’s stock, valued at $2,167,943.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, March 27th, Thomas Catinazzo sold 348 shares of Relay Therapeutics stock. The stock was sold at an average price of $7.70, for a total value of $2,679.60.

Relay Therapeutics Price Performance

NASDAQ:RLAY opened at $6.59 on Tuesday. The firm has a market capitalization of $872.12 million, a price-to-earnings ratio of -2.35 and a beta of 1.63. The company’s 50-day moving average is $8.15 and its two-hundred day moving average is $8.81. Relay Therapeutics, Inc. has a 1-year low of $5.70 and a 1-year high of $13.32.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, February 22nd. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 42.43%. During the same period last year, the business posted ($0.56) EPS. As a group, equities analysts anticipate that Relay Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Relay Therapeutics

Several large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC acquired a new stake in shares of Relay Therapeutics in the first quarter valued at $79,000. Los Angeles Capital Management LLC boosted its holdings in Relay Therapeutics by 25.7% during the 1st quarter. Los Angeles Capital Management LLC now owns 13,939 shares of the company’s stock valued at $116,000 after acquiring an additional 2,850 shares during the period. Victory Capital Management Inc. acquired a new position in Relay Therapeutics in the 4th quarter valued at about $126,000. Aigen Investment Management LP purchased a new stake in Relay Therapeutics during the third quarter worth about $142,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in shares of Relay Therapeutics during the first quarter worth about $146,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on RLAY. Leerink Partnrs reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research note on Thursday, February 22nd. Stifel Nicolaus raised their price objective on shares of Relay Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $26.00.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.